Neuraxis Appoints New CMO, Adds Directors

Ticker: NRXS · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1933567

Neuraxis, INC 8-K Filing Summary
FieldDetail
CompanyNeuraxis, INC (NRXS)
Form Type8-K
Filed DateMar 11, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.001, $60,000, $50,000
Sentimentneutral

Sentiment: neutral

Topics: executive-appointment, board-of-directors, governance

TL;DR

Neuraxis just hired a new CMO and added two board members, David L. Bear and Sarah E. Johnson.

AI Summary

Neuraxis, Inc. announced on March 7, 2024, the appointment of Dr. David L. Bear as Chief Medical Officer and the election of Mr. David L. Bear and Ms. Sarah E. Johnson to its Board of Directors. The company also disclosed compensatory arrangements for these individuals, though specific dollar amounts were not detailed in this filing.

Why It Matters

The appointment of a new Chief Medical Officer and board members can signal strategic shifts or new directions for the company's medical and governance strategies.

Risk Assessment

Risk Level: low — This filing primarily concerns executive appointments and board changes, which are routine corporate governance events and do not inherently represent significant financial risk.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Medical Officer for Neuraxis, Inc.?

Dr. David L. Bear has been appointed as the new Chief Medical Officer for Neuraxis, Inc.

Who were elected to the Board of Directors of Neuraxis, Inc.?

Mr. David L. Bear and Ms. Sarah E. Johnson were elected to the Board of Directors of Neuraxis, Inc.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is March 7, 2024.

What is the principal executive office address for Neuraxis, Inc.?

The principal executive office address for Neuraxis, Inc. is 11611 N. Meridian St, Suite 330, Carmel, IN 46032.

What is the SIC code for Neuraxis, Inc.?

The Standard Industrial Classification (SIC) code for Neuraxis, Inc. is 3845, which corresponds to ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS.

Filing Stats: 876 words · 4 min read · ~3 pages · Grade level 10.2 · Accepted 2024-03-11 08:50:26

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 11, 2024 NEURAXIS, INC. By: /s/ Brian Carrico Name: Brian Carrico Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing